{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:33:41Z","timestamp":1793475221493,"version":"4.5.0"},"reference-count":73,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.2169\/internalmedicine.2035-18","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T22:34:43Z","timestamp":1547073283000},"page":"1199-1207","source":"Crossref","is-referenced-by-count":42,"title":["Clinical and Genetic Aspects of Beh\u00e7et's Disease in Japan"],"prefix":"10.2169","volume":"58","author":[{"given":"Yohei","family":"Kirino","sequence":"first","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University, Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University, Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behcet syndrome: a contemporary view. Nat Rev Rheumatol 14: 119, 2018."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sakane T, Takeno M, Suzuki N, Inaba G. Beh\u00e7et's disease. N Engl J Med 341: 1284-1291, 1999.","DOI":"10.1056\/NEJM199910213411707"},{"key":"3","unstructured":"3. Kirino Y, Ideguchi H, Takeno M, et al. Continuous evolution of clinical phenotype in 578 Japanese patients with Beh\u00e7et's disease: a retrospective observational study. Arthritis Res Ther 18: 217, 2016."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Beh\u00e7et disease: evolution of clinical manifestations. Medicine (Baltimore) 90: 125-132.","DOI":"10.1097\/MD.0b013e318211bf28"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Iwata D, Mizuuchi K, Aoki K, et al. Serial frequencies and clinical features of uveitis in Hokkaido, Japan. Ocul Immunol Inflamm 25: S15-S18, 2017.","DOI":"10.1080\/09273948.2016.1184286"},{"key":"6","unstructured":"6. Mizushima Y, Inaba G, Mimura Y. Guide for the diagnosis of Beh\u00e7et's disease. Report of Beh\u00e7et's Disease Research Committee, Japan 8-17, 1987 (in Japanese)."},{"key":"7","first-page":"1078","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et's disease null","year":"1990","unstructured":"7. Criteria for diagnosis of Beh\u00e7et's disease. International study group for Beh\u00e7et's disease. Lancet 335: 1078-1080, 1990.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"8","unstructured":"8. Kaneko F, Togashi A, Nomura E, Nakamura K. A new diagnostic way for Beh\u00e7et's disease: skin prick with self-saliva. Genet Res Int 2014: 581468, 2014."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28: 338-347, 2014.","DOI":"10.1111\/jdv.12107"},{"key":"10","unstructured":"10. Davatchi F, Shahram F, Chams-Davatchi C, et al. Beh\u00e7et's disease: from East to West. Clin Rheumatol 29: 823-833, 2010."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kimura S, Kuroda J, Akaogi T, Hayashi H, Kobayashi Y, Kondo M. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis-Beh\u00e7et's syndrome. Leuk Lymphoma 42: 115-121, 2001.","DOI":"10.3109\/10428190109097683"},{"key":"12","unstructured":"12. Firestein GS, Gruber HE, Weisman MH, Zvaifler NJ, Barber J, O'Duffy JD. Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondritis and Beh\u00e7et's disease. Am J Med 79: 65-72, 1985."},{"key":"13","unstructured":"13. Schwartz T, Langevitz P, Zemer D, Gazit E, Pras M, Livneh A. Beh\u00e7et's disease in Familial Mediterranean fever: characterization of the association between the two diseases. Semin Arthritis Rheum 29: 286-295, 2000."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cho SB, Kim J, Kang SW, et al. Renal manifestations in 2007 Korean patients with Beh\u00e7et's disease. Yonsei Med J 54: 189-196, 2013.","DOI":"10.3349\/ymj.2013.54.1.189"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 140: 784-790, 2010.","DOI":"10.1016\/j.cell.2010.03.002"},{"key":"16","unstructured":"16. Hirohata S, Kikuchi H, Sawada T, et al. Clinical characteristics of neuro-Beh\u00e7et's disease in Japan: a multicenter retrospective analysis. Mod Rheumatol 22: 405-413, 2012."},{"key":"17","unstructured":"17. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Beh\u00e7et's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54: 213-220, 1999."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Aramaki K, Kikuchi H, Hirohata S. HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Beh\u00e7et's disease. Mod Rheumatol 17: 81-82, 2007.","DOI":"10.1007\/s10165-006-0541-z"},{"key":"19","unstructured":"19. Hirohata T, Kuratsune M, Nomura A, Jimi S. Prevalence of Beh\u00e7et's syndrome in Hawaii. With particular reference to the comparison of the Japanese in Hawaii and Japan. Hawaii Med J 34: 244-246, 1975."},{"key":"20","unstructured":"20. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome. Ann Rheum Dis 77: 808-818, 2018."},{"key":"21","unstructured":"21. Mizushima Y, Matsuda T, Hoshi K, Ohno S. Induction of Beh\u00e7et's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 15: 1029-1030, 1988."},{"key":"22","unstructured":"22. Kim DY, Choi MJ, Cho S, Kim DW, Bang D. Changing clinical expression of Beh\u00e7et disease in Korea during three decades (1983-2012): chronological analysis of 3674 hospital-based patients. Br J Dermatol 170: 458-461, 2014."},{"key":"23","first-page":"1383","volume":"2","author":"S Ono","year":"1973","unstructured":"23. Ono S, Aoki K, Sugiura S, Nakayama E, Itakura K. Letter: HL-A5 and Beh\u00e7et's disease. Lancet 2: 1383-1384, 1973.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"24","unstructured":"24. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51\/B5 and the risk of Beh\u00e7et's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 61: 1287-1296, 2009."},{"key":"25","unstructured":"25. Horie Y, Meguro A, Ohta T, et al. HLA-B51 Carriers are susceptible to ocular symptoms of Beh\u00e7et disease and the association between the two becomes stronger towards the East along the Silk Road: a literature survey. Ocul Immunol Inflamm 25: 37-40, 2017."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh\u00e7et's disease susceptibility loci. Nat Genet 42: 703-706, 2010.","DOI":"10.1038\/ng.624"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Beh\u00e7et's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 45: 202-207, 2013.","DOI":"10.1038\/ng.2520"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh\u00e7et's disease. Nat Genet 42: 698-702, 2010.","DOI":"10.1038\/ng.625"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Takeuchi M, Mizuki N, Meguro A, et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Beh\u00e7et's disease susceptibility. Nat Genet 49: 438-443, 2017.","DOI":"10.1038\/ng.3786"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Beh\u00e7et's syndrome. Medicine (Baltimore) 53: 343-364, 1974.","DOI":"10.1097\/00005792-197409000-00002"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. McGonagle D, Aydin SZ, Gul A, Mahr A, Direskeneli H. 'MHC-I-opathy'-unified concept for spondyloarthritis and Beh\u00e7et disease. Nat Rev Rheumatol 11: 731-740, 2015.","DOI":"10.1038\/nrrheum.2015.147"},{"key":"32","unstructured":"32. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Beh\u00e7et's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 38: 728-733, 1999."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Beh\u00e7et's disease. Inflamm Bowel Dis 17: 605-613, 2011.","DOI":"10.1002\/ibd.21313"},{"key":"34","unstructured":"34. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome. Ann Rheum Dis 77: 808-818, 2018."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Beh\u00e7et's syndrome. N Engl J Med 322: 281-285, 1990.","DOI":"10.1056\/NEJM199002013220501"},{"key":"36","unstructured":"36. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis. J Rheumatol 31: 1362-1368, 2004."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383-1395, 2010.","DOI":"10.1056\/NEJMoa0904492"},{"key":"38","unstructured":"38. Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Beh\u00e7et disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95: e3863, 2016."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Beh\u00e7et's disease. Clin Gastroenterol Hepatol 13: 940-948.e3, 2015.","DOI":"10.1016\/j.cgh.2014.08.042"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Beh\u00e7et's syndrome-a phase 2, placebo-controlled study. N Engl J Med 372: 1510-1518, 2015.","DOI":"10.1056\/NEJMoa1408684"},{"key":"41","unstructured":"41. Ohtsuki M, Okubo Y, Komine M, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol 44: 873-884, 2017."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Kim J, Krueger JG. Highly effective new treatments for psoriasis target the IL-23\/Type 17 T cell autoimmune axis. Annu Rev Med 68: 255-269, 2017.","DOI":"10.1146\/annurev-med-042915-103905"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Tang H, Jin X, Li Y, et al. A large-scale screen for coding variants predisposing to psoriasis. Nat Genet 46: 45-50, 2014.","DOI":"10.1038\/ng.2827"},{"key":"44","unstructured":"44. Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 25: 514-521, 2015."},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357: 977-986, 2007.","DOI":"10.1056\/NEJMc072855"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2: Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42: 985-990, 2010.","DOI":"10.1038\/ng.694"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Evans DM, Spencer CC, Pointon JJ, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 43: 761-767, 2011.","DOI":"10.1038\/ng0911-919a"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Takeuchi M, Ombrello MJ, Kirino Y, et al. A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Beh\u00e7et's disease in HLA-B*51 carriers. Ann Rheum Dis 2016.","DOI":"10.1136\/annrheumdis-2015-209059"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Guasp P, Barnea E, Gonz\u00e1lez-Escribano MF, et al. The Beh\u00e7et's disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing. J Biol Chem 292: 9680-9689, 2017.","DOI":"10.1074\/jbc.M117.789180"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Kim DK, Kabat J, Borrego F, Sanni TB, You CH, Coligan JE. Human NKG2F is expressed and can associate with DAP12. Mol Immunol 41: 53-62, 2004.","DOI":"10.1016\/j.molimm.2004.01.004"},{"key":"51","doi-asserted-by":"publisher","unstructured":"51. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729, 1999.","DOI":"10.1126\/science.285.5428.727"},{"key":"52","unstructured":"52. Suarez-Alvarez B, Lopez-Vazquez A, Baltar JM, Ortega F, Lopez-Larrea C. Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention. Am J Transplant 9: 251-257, 2009."},{"key":"53","unstructured":"53. Mizuki N, Ota M, Kimura M, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Beh\u00e7et disease. Proc Natl Acad Sci U S A 94: 1298-1303, 1997."},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Yasuoka H, Okazaki Y, Kawakami Y, et al. Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Beh\u00e7et's disease. Arthritis Rheum 50: 3658-3662, 2004.","DOI":"10.1002\/art.20597"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Erer B, Takeuchi M, Ustek D, et al. Evaluation of KIR3DL1\/KIR3DS1 polymorphism in Beh\u00e7et's disease. Genes Immun 17: 396-399, 2016.","DOI":"10.1038\/gene.2016.36"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Kirino Y, Zhou Q, Ishigatsubo Y, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Beh\u00e7et disease. Proc Natl Acad Sci U S A 110: 8134-8139, 2013.","DOI":"10.1073\/pnas.1306352110"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Zhang F, Liu H, Chen S, et al. Identification of two new loci at IL23R and RAB32 that influence susceptibility to leprosy. Nat Genet 43: 1247-1251, 2011.","DOI":"10.1038\/ng.973"},{"key":"58","doi-asserted-by":"publisher","unstructured":"58. Xu H, Yang J, Gao W, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513: 237-241, 2014.","DOI":"10.1038\/nature13449"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 17: 914-921, 2016.","DOI":"10.1038\/ni.3457"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Shimizu J, Kubota T, Takada E, et al. Bifidobacteria abundance-featured gut microbiota compositional change in patients with Beh\u00e7et's disease. PLoS One 11: e0153746, 2016.","DOI":"10.1371\/journal.pone.0153746"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet 48: 481-487, 2016.","DOI":"10.1038\/ng.3538"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361: 2033-2045, 2009.","DOI":"10.1056\/NEJMoa0907206"},{"key":"63","unstructured":"63. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002."},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Nakano H, Kirino Y, Takeno M, et al. GWAS-identified CCR1 and IL10 loci contribute to M1 macrophage-predominant inflammation in Beh\u00e7et's disease. Arthritis Res Ther 20: 124, 2018.","DOI":"10.1186\/s13075-018-1613-0"},{"key":"65","unstructured":"65. Zhou Q, Wang H, Schwartz DM, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 48: 67-73, 2016."},{"key":"66","unstructured":"66. Shoda R, Matsueda K, Yamato S, Umeda N. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr 63: 741-745, 1996."},{"key":"67","unstructured":"67. Kanai T, Matsuoka K, Naganuma M, Hayashi A, Hisamatsu T. Diet, microbiota, and inflammatory bowel disease: lessons from Japanese foods. Korean J Intern Med 29: 409-415, 2014."},{"key":"68","unstructured":"68. Jazayeri O, Daghighi SM, Rezaee F. Lifestyle alters GUT-bacteria function: linking immune response and host. Best Pract Res Clin Gastroenterol 31: 625-635, 2017."},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH. Identification of novel genetic susceptibility loci for Beh\u00e7et's disease using a genome-wide association study. Arthritis Res Ther 11: R66, 2009.","DOI":"10.1186\/ar2695"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Hou S, Yang Z, Du L, et al. Identification of a susceptibility locus in STAT4 for Beh\u00e7et's disease in Han Chinese in a genome-wide association study. Arthritis Rheum 64: 4104-4113, 2012.","DOI":"10.1002\/art.37708"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Lee YJ, Horie Y, Wallace GR, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Beh\u00e7et's disease. Ann Rheum Dis 72: 1510-1516, 2013.","DOI":"10.1136\/annrheumdis-2011-200288"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Xavier JM, Shahram F, Sousa I, et al. FUT2: filling the gap between genes and environment in Beh\u00e7et's disease? Ann Rheum Dis 74: 618-624, 2015.","DOI":"10.1136\/annrheumdis-2013-204475"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Kappen JH, Medina-Gomez C, van Hagen PM, et al. Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Beh\u00e7et disease. PLoS One 10: e0119085, 2015.","DOI":"10.1371\/journal.pone.0119085"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/9\/58_2035-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:49:58Z","timestamp":1662770998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/9\/58_2035-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2035-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}